Last year it offered a disappointing stretch for biotech, with fewer deals than expected and lots more headwinds. Endpoints News Editor-in-Chief John Carroll sat down with some of the industry’s top dealmakers to explore what happened, and what’s ahead in 2023. This transcript has been edited for brevity and clarity.
I’d say this is one of the most important conversations that’s going on right now. Particularly, of course, at JP Morgan, because so many people have come here, specifically to get involved in a deal, to see what they can do about a deal, to see what the potential deal is, where things are headed, what the trends are. Everything that we’re going to be covering here in the next hour.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.